17th INTERNATIONAL MEDICINE AND HEALTH SCIENCES RESEARCHERS CONGRESS
Future Vısıon in Medıcınal Treatment of Atherosclerosıs
Atherosclerosis is the leading cause of coronary artery disease, which is the most common cause of death in the world. Today, drug treatment of atherosclerosis-related diseases can effectively control the progression of atherosclerosis, but due to factors such as poor bioavailability, nonspecific distribution and high toxicity that may occur with the use of these drugs, they have not had satisfactory therapeutic effects. Therefore, the search for new treatments continues to accelerate. As a result of advances in today's knowledge and technology, significant developments have been made for new treatment methods. In studies conducted on atheroma plaque, it was observed that a monoclonal antibody developed against extracellular matrix glycosamino glycans, which are an important substance for the development of atheroma plaque, significantly reduced the formation of foam cells. In recent years, it has been shown that treatments with inhibitor drugs developed against chronic inflammation, which has been revealed to play an important role in the development and progression of atherosclerosis, especially the NLRP3 inflammasome, which is one of the main molecules of inflammation, significantly reduced the formation of atherosclerotic lesions. Genomic treatments, especially in lipid metabolism; treatments developed on PCSK9 and molecules regulating miRNAs have been shown to have healing effects on atheroma plaque and lipid accumulation. Nanomaterials, shown as future drug models, are planned to be used in atherosclerosis to carry other drugs and to reveal their own therapeutic effects. Among the new approaches on the lipid profile underlying the physiopathology of atherosclerosis, PPARƔ and niacin treatments stand out. In conclusion; although there are promising new therapeutic agents and treatment pathways on atherosclerosis, it seems possible that it will be realized in the near future, although we need to wait a while longer to achieve absolute benefit due to the large number and variety of mechanisms leading to pathology.
